Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo
CEPI has pledged $50 million to Moderna to accelerate the development of an mRNA vaccine targeting the Bundibugyo ebolavirus. This initiative aims to address the ongoing outbreak in the Democratic Republic of the Congo through rapid clinical testing and manufacturing.
Why it matters
Accelerated vaccine development is essential for containing infectious disease outbreaks and preventing global health crises.
Vaccine development Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo Amid a raging Ebola outbreak, officials urgently accelerate development of vaccines.
Factual reporting on health policy and pharmaceutical development.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in